

References

- Ahmed A, Keefe EB. Current indications and contraindications for liver transplantation. ***Clin. Liver Dis.* 2007; 11: 227-247.**
- Aikata H, Takaishi H, Kawakami Y, et al. Telomere reduction in human liver tissues with age and chronic inflammation. ***Exp. Cell Res.* 2000; 256: 578–582.**
- Al Sebayel M, Ramirez C, Abou Ella K. The first 100 liver transplants in Saudi Arabia. ***Transpl. Proc.* 2001; 33: 2709.**
- Al Sofayana .M.S, Ibrahimc .A, Helmyd. A, et al. Nuclear Imaging of the Liver: Is There a Diagnostic Role of HIDA in Posttransplantation?. ***Transpl. proc.* 2009; 41(1): 201-207.**
- Alagoz Oguzhan, Lisa M. Maillart, Andrew J. Schaefer and Mark S. Roberts. Choosing Among Living-Donor and Cadaveric Livers. ***Manegment Science* 2007; 53(11): 1702-1715.**
- Alary M, Joly JR, Vincelette J, et al. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. ***AJ of Public Health* 2005; 95(3):502–5.**
- Albano.E, S.W. French and M. Ingelman-Sundberg. Hydroxyethyl radicals in ethanol hepatotoxicity. ***Front. Biosc.* 1999; 4: 533–540.**
- Andrew R. Haas and Michael S. Machuzak. Hepatic hydrothorax: current approaches to diagnosis and therapy. ***AJG* 2009; 11 (3): 114-117.**

- Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. **Liver Transpl.** 2003; 9: 451–462.
- Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. **Gut** 2003; 52: 879-85.
- Angulo P. Nonalcoholic fatty liver disease and liver transplantation. **Liver Transpl.** 2006; 12: 523–534.
- Ann Surg. Use of severely steatotic grafts in liver transplantation. **Nat. Clin. Pract. Gastroenterol. Hepatol.** 2008; 248(1): 142-3.
- Ansari-Lari MA, Muzny DM, Lu J, et al. A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. **Genome Res.** 2002; 6 (4): 314–26.
- Arash Nickkholgh, Jürgen Weitz, Jens Encke, et al. Utilization of extended donor criteria in liver transplantation. **Transpl.** 2007; 22: 27–36.
- Arthos J, Deen K C, Chaikin M A, et al. Identification of the residues in human CD4 critical for the binding of HIV. **Cell** 1989; 57: 469-481.
- Avolio .A.W, Agnes.S, Gasbarrini.A et al. Prognostic Value of MELD Score and Donor Quality in Liver Transplantation: Implications for the Donor Recipient Match. **Transpl. proc.** 2006; 38(4): 1059-1062.

- Bahr M.J, Beckermann J.G, Rifai K, et al. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. **Transpl. Proc.** 2005; 37: 1703–1704.
- Banff Working Group, Liver biopsy interpretation for causes of late liver allograft dysfunction, **Hepatology**. 2006; 44:489–501.
- Bar ML, Belghiti J, Villamil FG, et al. A report of the Vancouver Forum of the care of the live organ donor. Lung, liver, pancreas and intestine data and medical guidelines .**Transpl.** 2006; 81: 1373-1385.
- Battifora H. Diagnostic uses of antibodies to keratins: a review and immunohistochemical comparison of seven monoclonal and three polyclonal antibodies. **Progress in Surgical Pathol.** 2001; 6:1–15.
- Bedossa P, Poynard T, et al. The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. **Hepatology**. 1996; 24: 289-93.
- Bellentani S and Tiribelli C . The spectrum of liver disease in the general population: lesson from the Dionysos study. **Hepatology**, 2001; 35: 531–7.
- Bennett GA, Velleman RD, Barter G. Gender differences in sharing injecting equipment by drug users in England. **AIDS Care** 2000; 12(1): 77-87.
- Berenguer M, Prieto M and Rayon J.M et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. **Hepatology**. 2000; 32: 852–858.

- Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. **Hepatol.** 2002; 36: 202–210.
- Bettelli E, Oukka M and Kuchroo V. T(H)-17 cells in the circle of immunity and autoimmunity. **Nat. Immunol.** 2007; 8: 345–350.
- Bilzer M, Gerbes AL. Preservation injury of the liver: mechanisms and therapeutic strategies. **Hepatol.** 2000; 32: 508-515.
- Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long term follow up and evaluation of features for histopathological staging. **Transpl.** 2000; 32: 2330-2336.
- Bolton EM. Regulatory T cells. Natural or inatural or in clued. **Transpl.** 2005; 97: 643-645.
- Bosch.F.X, J. Ribes, R. Cleries and M. Diaz. Epidemiology of hepatocellular carcinoma. **Clin. Liver Dis.** 2005; 9 :191–211.
- Bravo, AA, Sheth, SG, Chopra, S. Liver biopsy. **N Engl. J. Med.** 2001; 344:495.
- Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. **Transpl.** 2002; 74: 522–526.
- Briceno J, Padillo J, Rufian S, Solorzano G, Pera C. Assignment of steatotic livers by the Mayo model for end-stage liver disease. **Transpl. Int.** 2005; 18: 577–583.

- Brown KA. Liver transplantation. **Curr. Opin. Gastroenterol.** 2005; 21(3): 331-6.
- Brown R, Rush Sh, Rosen HR et al. Liver and intestine transplantation. **Am. J. transpl.** 2004; 4(9):81-92.
- Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? **Transpl.** 2003; 76: 340–343.
- Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. **Am. J. Transpl.** 2004; 4: 686–693.
- Burton J.R. and Rosen H.R. Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. **Clin. Gastroenterol. Hepatol.** 2005; 3: 700–704.
- Busuttil R, Tanaka K. The utility of marginal donors in liver transplantation. **Liver transpl.** 2003; 9:651-663.
- Carambia Antonella and Johannes Herkel. CD4 T cells in hepatic immune tolerance. **Immunity** 2009; 34(1): 23-28.
- Carmiel-Haggai M, Fiel M.I and Gaddipati H.C et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. **Liver Transpl.** 2005; 11: 1567–1573.
- Carrion J.A, Navasa M and Garcia-retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. **Gastroenterol.** 2007; 132 : 1746–1756.

- Carpentier A, Conti F, Stenard F, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. **AJ Transpl.** 2009; 9: 2102-2112.
- Cerutti E, Stratta C, Romagnoli R, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. **Liver Transpl.** 2006; 12:1253–1259.
- Chen C.L., S.T. Fan, S.G. Lee, M. Makuuchi and K. Tanaka, Living-donor liver transplantation: 12 years of experience in Asia, **Transpl.** 2003; 15(75): 6–11.
- Chiu C.M, S.H. Yeh, P.J. Chen et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. **Proc. Nat. Acad. Sci. USA** 2007; 104: 2571–2578.
- Chopra K.B, Demetris A.J, Blakolmer K, I. Dvorchik, T. Laskus and L.F. Wang et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. **Transpl.** 2003; 76: 1487–1491.
- Costantino Fondevila and Rafik M. Ghobrial. Donor selection and management. **Transpl, of the liver** 2005; 35:515.
- Cougot .D, C. Neuveut and M.A. Buendia, HBV induced carcinogenesis. **J. Clin. Virol.** 2005; 34 (1): 75–78.
- Crawford AR, Lin x-z, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. **Hepatol.** 2000 ;28 :323-331.

- Datta Gs, Hudson M, Burroughs AK, et al. Grading of cellular rejection after orthotopic liver transplantation. **Hepatol.** 1995; **21(1): 46-57.**
- Datta GS. Histopathological scoring of chronic viral hepatitis. **Hep. B Annual** 2004; **1: 92-112.**
- Dawn Sears and Gary L. Davis. Natural history of hepatitis C. **Transpl. of the liver** 2005; **9: 129-141.**
- De Carlis L, Colella G, Sansalone CV, et al. Marginal donors in liver transplantation: the role of donor age. **Transpl. Proc.** 1999; **31: 397–400.**
- Demetris A, Adams D, Bellamy C, Blakolmer K, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. **Hepatol.** 2000; **31: 792-799.**
- Demetris A.J, Batts K.P, Dhilon A.p, et al. Banff schema for grading liver allograft rejection : An international Consensus document. **Hepatol.** 1997; **25(3) :658-663.**
- Demetris A.J, Adam D, Bellamy C, et al. Update of the international Banff schema for liver allograft rejection: Working recommendations for histopathologic staging and reporting of chronic rejection. An international panel. **Hepatol.** 2000; **31: 792-799.**
- Demetris A.J, Ruppert K, Dvorchik I, et al. Real time monitoring of acute liver allograft rejection using the Banff schema. **Transpl.** 2002; **74: 1290-1296.**

- Demetris A.J, Eghtesad B and Marcos A, et al. Recurrent Hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. **Am. J. Surg. Pathol.** 2004 ;28 : 658–669.
- Demetris AJ, Ninevini CJ, et al. Transplantation pathology of the liver. In: Odze RD, Goldblum JR, eds, Surgical pathology of GI tract, liver, biliary tract and pancreas .2nd edn. **Philadelphia: Saunders/ Elsevier** 2009: 1169-1229.
- Devine L, Sun J, Barr M, Kavathas P .Orientation of the Ig domains of CD8 alpha beta relative to MHC class I. **J Immunol.** 1999; 162 (2): 846–51.
- Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. **Transpl.** 1999; 64:1582–1584.
- Doherty DG, O’farrelly c. Innate and adaptive lymphoid Donor transplanted for decompensate End Stage Liver disease .**Hepatol.** 2000; 33: 54-60.
- Dollinger M, S.E. Howie, J.N. Plevris, et al, Intrahepatic proliferation of ‘naive’ and ‘memory’ T cells during liver allograft rejection: primary immune response within the allograft. **FASEB J** 1998; 12(11): 939–947.
- Donato .M.F, Rigamonti C and Clambo M. Can protocol liver biopsy be avoided to evaluate post transplant hepatitis C recurrence. **Digestive and liver dis.** 2010; 42(4):307.

- Dtroty D, Barr M, Kavathas P. Essential markers in malignant lymphoma: a diagnostic approach. **AJ. Pathol.** **2001; 159(5):1751–1761.**
- Edamoto.Y, A. Hara, W. Biernat, L. et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. **Int. J. Cancer** **2003; 106: 334–341.**
- El- Bolkainy MN. Hepatobiliary cancer .Topographic pathology of cancer M.A.N. El-Bolkainy MN, Tarek N. Elbolkainy. **National Cancer Institute, Cairo University 2005.**
- El- Gazzaz H. Galal and El- Elemi .H .Azza. Liver transplantation in Egypt from West to East. **Transpl. research and risk management 2010; 2010: 2.**
- El-Raziky MS, M El-Hawary, G Esmat et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. **World J. Gastroenterol.** **2007 ;13(12): 1828-1832.**
- El-Sawy T, Belperio J, Strieter R, et al. Inhibition of polymorphonuclear leukocyte- mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. **Circulation** **2005; 112 : 320–331.**
- Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter Symposium. **AJ. Transpl.** **2003; 3:1481–1467.**

- Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. **AJ. Transpl.** 2006; 6: 783–790.
- Ferrell L.D, Theise N.D and Scheuer P.J. Acute and chronic viral hepatitis. **Pathol. of the liver** 2002; 7: 345-348.
- Fiebig H, Behn I, Gruhn R, et al. Characterization of a series of monoclonal antibodies against human T cells. **Allerg. Immunol.** 1984; 30 (4): 242–50.
- Firpi, RJ, Soldevila-Pico, C, Abdelmalek, MF, et al. Short recovery time after percutaneous liver biopsy: should we change our current practices?. **Clin. Gastroenterol. Hepatol.** 2005; 3: 926.
- Forman LM, J.D. Lewis, J.A. Berlin, H.I. Feldman and M.R. Lucey. The association between hepatitis C infection and survival after orthotopic liver transplantation. **Gastroenterol.** 2002; 122: 889–896.
- Franzen LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. **Mod. Pathol.** 2005; 18:912–916.
- Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. **Liver Transpl.** 2002; 8: 851-8.
- Gao G, Jakobsen B .Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. **Immunol. Today** 2000; 21 (12): 630–6.

- Garcia- Retortillo M, Forns X and Folio A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. **Hepatol. 2002; 35: 680–687.**
- Gay D, Maddon P, Sekaly R, et al. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. **Nature 1987; 328: 626-629.**
- George N Ioannou, James D Perkins and Robert L. Carithers Jr. Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. **Gastroentrol. 2008; 134(5): 1342-1351.**
- Gerald.L, Nancy L and John P. Rejection after transplantation. **Transpl. of liver 2005; 72:1167-1179.**
- Gershwin M. Eric, Vierling M.John, Michael. Acute and chronic rejection of liver allograft. **Liver Immunol. 2007; 32:42.**
- Gilks, W. R., Spiegelhalter, D. J. & Cobbold, S. P. Leukocyte Typing Database III. **Wikipedia 2000.**
- Gondolessi G.E, S. Roayaie and L. Munoz et al. Adult Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: Extending UNOS Priority Criteria. **Ann. Surg. 2004; 239: 142–149.**
- Goriely S and Goldman M. The interleukin-12 family: new players in transplantation immunity?, **AJ. Transpl. 2007; 7: 278–284.**

- Grazi GL, Cescon M, Ravaioli M, et al. A revised consideration on the use of very aged donors for liver transplantation. **AJ. Transpl.** 2001); 1: 61–68.
- Gregory J. Gores, David M. Nagorney and Charles B. Rosen. Cholangiocarcinoma: Is transplantation an option? For whom? **Hepatol.** 2007; 47(4): 455-459.
- Gruener Hubert, Jung Maria and Schirren Carl. Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control. **J antimicrobial chemotherapy** 2004; 54: 17-20.
- Habib S, Berk B, Chang C, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. **Liver Transpl.** 2006; 12: 440-447.
- Harrington, LE; Hatton, RD; Mangan, PR. Et al. "Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages". **Nat. Immunol.** 2005; 6 (11): 1023–32.
- Haugk Beate, Ahmed El-Refaieb, Alastair David Burt. Pathology of liver transplantation. **Curr. diagnostic pathol.** 2007; 13(1) :75-84.
- Helmy.A. Post liver transplantation complications. **Saudi J. Gastroentrol.** 2006; 12(1): 39.

- Herrero.J.I, M. Lorenzo and J. Quiroga et al. De Novo Neoplasia after Liver Transplantation: An Analysis of Risk Factors and Influence on Survival. **Liver Transpl.** 2004; 11: 89–9.
- Hilgard P, Kahraman A, Lehmann N, et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. **World J. Gastroenterol.** 2006; 12: 697–702.
- Hübscher G Stefan. European grading for acute allograft rejection. **Hepatol.** 1996; 61: 817.
- Hübscher G Stefan. Central perivenulitis. A common and potentially important finding in late posttransplant liver biopsies. **Liver transpl.** 2008; 14(5): 596-600.
- Hubscher SG, Portmann BC. Transplantation pathology. In: Burt AD, Portmann BC, Ferrell LD MacSween's Pathology of the Liver. 5th ed. London: **Churchill-Living stone** 2007: 815-861.
- .Human Cell Differentiation Molecules Council (successor to the HLDA Workshops), 2009.
- Huo T.I, X.W. Wang, M. Forgues et al. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. **Oncogene** 2001; 20: 3620–3628.
- Ian C. Carmody and Pauline W. Chen. Treatment of acute and chronic rejection. **Transpl. of liver** 2005; 77: 1263-1294.

- Iannacone M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. **Nat. Med.** 2005; 11: 1167–1169.
- Iannacone M. et al. Pathogenetic and antiviral immune responses against hepatitis B virus. **Future Virology** 2006; 1 (2): 189–196..
- Ibrahim, A.A.E. The prophylactic effect of whitethorn extract on the immune system in induced hypercholesterolaemic in rats. **Egyp. J. Nat. Tox.** 2006; 3: 118-140.
- International Working party, 1995.
- Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. **J. Hepatol.** 1995; 22: 696-9.
- Isobe M, Huebner K, Maddon P et al. The gene encoding the T-cell surface protein T4 is located on human chromosome 12". **Proc. Nat. Acad. Sci. U.S.A** 2001; 83 (12): 4399–402.
- James f, Trotter P and Galkam I. Donor and recipient evaluate and selection for adult-to –adult right hepatic lobe liver transplantation. **Transpl. of the liver** 2005; 44: 663.
- Jarnagin W.R. Cholangiocarcinoma of the extrahepatic bile ducts. **Semin. Surg. Oncol.** 2000; 19: 156–176.
- Jimenez M, Turrion VS, Lucena JL, Alvira LG, Ardaiz J. Late liver retransplantation versus early liver retransplantation: indications and results. **Transpl. Proc.** 2002; 34: 304-305.
- Jimenez Romero C, Moreno Gonzalez E, et al. Use of octogenarian livers safely expands the donor pool. **Transpl.** 1999; 68:572–575.

- Joey Christine Papa. Indications of liver transplantation. **The Mount Sinai J. of Med.**2007; 73: 8.
- John F, Renzcinduy J, kin S and Jean C.E. Outcomes of living donor liver transplantation. **Transpl. of the liver** 2005 ; 47: 713-714.
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. **Hepatol.** 2001; 33: 464-70.
- Karen Dente. Donor risk remains a challenge in liver transplantation. **International liver transplant society 13th Annual international congress, 2007.**
- Kauffman HM. The United Network for Organ Sharing position on using donors with primary central nervous system malignancies. **Transpl.** 2005; 79:622–623.
- Khalaf H, El-Meteini M, El-Sefi T, et al. Evolution of living donor liver transplantation in Egypt. **Saudi Med. J.** 2005; 26(9): 1394-1397.
- Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. **Liver Transpl.** 2006; 12:1496–1503.
- Knapp, W. et al. Leukocyte Typing IV: White Cell Differentiation Antigen. **Wikipedia** 2000.

- Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. **Hepatology**. 1981; 1: 431-435
- Krishnamurthy T, Gerbail and Krishnamurthy Shakuntala. Types of liver transplantation. **Nuclear hepatology**. 2009; 13: 347-351.
- Kubota Nobuyuki, Masahiko Sugitani, Seigo Takano, et al. Correlation between acute rejection severity and CD8-positive T cells in living related liver transplantation. **Transplantation Immunology**. 2006; 16(1): 60-64.
- Kumar V, Mitchell RW, Abbas A. The gastrointestinal tract. In Robbins Pathologic Basis of Disease. 8th ed. Philadelphia, London, Toronto, Montreal, WB. Saunders company 2010; 8: 881.
- Laurent-Puig P, Legoix O, Bluteau et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. **Gastroenterology**. 2001; 120: 1763–1773.
- Lazaridis KN and Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. **Semin. Liver Dis.** 2006; 26:42–51.
- Leahy DJ, Axel R, Hendrickson WA. Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 Å resolution. **Cell** 1992; 68 (6): 1145–62.

- Lefkowitch JH. Diagnostic issues in liver transplantation pathology. **Clin. Liver Dis.** 2002; 6: 555–570.
- Lennart E Franzén, Mattias Ekstedt, Stergios Kechagias and Lennart Bodin. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies. **Transpl.** 2005; 66:356–360.
- Leong FJW-M and Leong AS-Y. Essential markers in malignant lymphoma: a diagnostic approach. **J. of Histotechnol.** 2002; 25(4): 215–227.
- Liang T.J and Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. **Gastroenterol.** 2004; 127 (5): 62–71.
- Liang T.Jake, Barbara Rehermann, Leonard B. Seeff, and Jay H. Hoofnagle. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. **Intern. Med.** 2000; 132: 297-299.
- Lok A.S, Hepatitis B infection: pathogenesis and management. **J. Hepatol.** 2000; 32: 89–97.
- Loong C, Hsieh H, Lui W, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. **J. Pathol.** 2002; 197: 322–332.
- Lorenzini S, Gitto S, Grandini E, Andreone P, Bernardi M. Stem cells for end stage liver disease: How far have we got? **World J. Gastroenterol.** 2008; 14(29): 4593-4599.
- Lovell MO, Speeg KV, Halff GA, Molina DK, Sharkey FE. Acute hepatic allograft rejection: a comparison of patients with and

without centrilobular alterations during first rejection episode.
Liver transpl. 2004; 10(3): 369-73.

- Lumbreras C, Sanz F, Gonzalez A, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. **Clin. Infect. Dis. 2001; 33:722–726.**
- Lunz JG, Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells. **AJ. Pathol. 2001; 158: 1379-1390.**
- Macsween R.N.M Desmet V.J, Roskamst, scothorne R.J. Deuelopmental anatomy - normal structure. **Pathol. of the liver 2002; 1: 52- 55.**
- Magder Fix AD, Mikhail NN Mohamed MK, Abdel-Hamid M Abdel-Aziz F, Medhat A Strickland GT. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. **International J. Epidemiology 2005; 34: 160–165.**
- Marco Antonio, Olivera-Martínez and Juan F. Gallegos-Orozco. Recurrent Viral Liver Disease (Hepatitis B and C) after Liver Transplantation. **AM. Research 2007; 38: 691-701.**
- Maria-Luisa Alegre, Sandrine Florquin and Michel Goldman. Cellular mechanisms underlying acute graft rejection: time for reassessment. **Curr. opinion in Immunol. 2007; 19(5): 563-568.**
- Marsh J.W, I. Dvorchik and M. Subotin et al. The Prediction of Risk of Recurrence and Time to Recurrence of Hepatocellular Carcinoma after Orthotopic Liver Transplantation: A Pilot Study. **Hepatol. 2003 ; 26: 444–450.**

- Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. **Epidemiol. Infection** 2005; 133: 127–136.
- Ma YI, Wang Guo-Dong, He Xiao, et al. Clinical and pathological analysis of acute cellular rejection following orthotopic liver transplantation. **Chinese MJ.** 2009; 122(12): 1400-1403.
- McCaughan W, J.S. Davies, J.A. Waugh, et al., A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabeling. **Hepatol.** 1990; 12(6): 1305–1313.
- McCaughan W and Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. **J. Hepatol.** 2004; 40:368–374.
- McLaren a, Friend p: Trends in organ preservation in liver transplantation. **Transpl.** 2003; 16:701-708.
- Megan L. Troxell, John P. Higgins, Neeraja Kambham. Evaluation of C4d Staining in Liver and Small Intestine Allografts. **Arch Pathol. & Lab. Med.** 2006; 130(10): 1489-1496.
- Meneu Diaz JC, Vicente E, Moreno Gonzalez E, Jimenez C, Nuno J, Lopez-Hervas P, et al. Indications for liver retransplantation: 1087 orthotopic liver transplantations between 1986 and 1997. **Transpl. Proc.** 2002; 34: 306.
- Michaels P.J, Fishbein M.C, Coluin R.B. Humoral rejection of human organ transplants. **Immunopathol.** 2003; 25: 119-140.

- Miller CM , Gondolesi GE , flormans et al. One hundred nine living donor liver transplants in adults and children: a single center experience. **Ann. Surg.** 2001;234: 301-311.
- Mohamed MK. Epidemiology of HCV in Egypt 2004. **The Afro-Arab Liver** 2004; 3(2): 41-52.
- Mokhtar N, Gouda I, Adel I. **Cancer Pathology Registry** 2007; 6:64.
- Moriya.K, H. Fujie, Y. Shintani, H. Yotsuyanagiet al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. **Nat. Med.** 2002: 1065–1067.
- Mudawi H, Helmy A, Kamel Y, Al Saghier M, et al. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation : Natural history and predictors of outcome. **Ann. Saudi Med.** 2009; 29: 91-7.
- Müller.C, Hepatocellular carcinoma–rising incidence, changing therapeutic strategies. **Wien. Med. Wochenschr** 2006; 156:404–409.
- Mulligan David C, Reddy Kunam ,Sudhakar Moss et al. New preservation solutions for use in liver transplantation. **Organ Transpl.** 2004; 9 (2).
- Nadalin S, Malogo M, Radtke A, et al. Current trends in liver donation. **Transpl. Int.** 2007; 20 :312-320.
- Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and pitfalls. **Lab. Med.** 1983; 14:767.

- Nanashima, P. Pillay and D.J. Verran *et al.*, Analysis of initial poor graft function after orthotopic liver transplantation: experience of an Australian single liver transplantation center. **Transpl. Proc.** 2002; 34: 1231–1235.
- Nardo B, Masetti M, Urbani L, et al. Liver transplantation from donors aged 80 years and over: pushing the limit. **AJ. Transpl.** 2004; 4: 1139–1147.
- Neipp M, Bektas H, Lueck R, et al. Liver transplantation using organs from donors older than 60 years. **Transpl. Int.** 2004; 17:416–423.
- Neuberger J, Adams D. Physiology of the transplanted liver. In: Norman D, Turka L. (eds). Primer on Transplantation, 2nd ed. Mt. Laurel, NJ: **Am. Soci. of Transpl.** 2001; 555-560.
- Neumann U.P, Berg T., Bahra B, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. **Hepatol.** 2004; 21: 830–836.
- Nguyen.H, Sankaran S. and Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. **Virol.** 2006; 354: 58–68.
- Nishida N., Nishimura T., Nagasaka T., et al. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. **Cancer Res.** 2007; 67: 4586–4594.

- Nydegger v, carrel t, laumpnier t, mohacsi p. New concepts in organ preservation . **Transpl. Immunol. of liver** 2005; 37: 545-558.
- Ohkohchi N. Mechanisms of preservation and ischemic/reperfusion injury in liver transplantation .**Transpl. Proc.** 2006; 34(7): 2670-2673.
- Ohkohchi Nobuhiro, Miyagi Shigehito, Oikawa Kohsei, et al. Effects of anti-inflammatory cytokine agent (FR167653) and serine protease inhibitor on warm ischemia –reperfusion injury of the liver graft.**Transpl.** 2004; 77(10): 1487-1493.
- Okabe H, Ikai K, Matsuo S, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. **Hepatol.** 2000; 31: 1073–1079.
- O' Garra A. Cytokines induce the development of functionally hetrogenous T helper cell subset. **Immunity** 2002; 8: 275.
- O' Keffee C, Baird AW, Nolan N, et al. Mast cell hyperplasia in chronic rejection after liver transplantation. **Liver transpl.** 2002; 8: 50-57.
- Pablo Souza, Thomas J., Anastacio M. et al. Morphologic features resembling transplant rejection in core biopsies of native livers from patients with Hepatitis C .**Human pathol.** 2009; 40(1): 92-97.

- Parkin D.M., Bray F., Ferlay J. and Pisani P. Estimating the world cancer burden: Globcan 2000. **Int. J. Cancer** 2001; **94**: 153–156.
- Perez CM, Suarez E, Torres EA, et al. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. **Int. J. Epidemiol.** 2005; **34(3)**: 593–9.
- Petersen A and Seed B. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. **Cell** 1988; **54**: 65-72.
- Pugh R, Murray-lyon I, Dawson J. Transection of the oesophagus v. for bleeding oesophageal varices.**Br. J. Surg.** 1973; **60**: 646-9.
- Rainer G, Uessner G, enirco B, et al. Donor selection and work up. **Living donor organ transplantation** 2008; **29**: 468-471.
- Rang, H. P. Pharmacology. Edinburgh: **Churchill Livingstone** 2005. ISBN 0-443-07145-4. :223
- Ray R.B, Lagging L.M, Meyer K, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. **Virus Res.** 2001; **37**: 209–220.
- Rea D.J, Munoz-Juarez, M.B., Farnell, J.H., et al. Major hepatic resection for hilar cholangiocarcinoma. **Arch. Surg.** 2004; **139** : 514–525.
- Regimbeau, E.K. Abdalla, J.N. Vauthey, G.Y. Lauwers, et al. Risk factors for early death due to recurrence after liver resection for

hepatocellular carcinoma: results of a multicenter study. **J. Surg. Oncol.** 2004; 85: 36–41.

- Reichman TW, Marino SR, Milner J, et al. Acute humoral rejection in an ABO compatible combined liver-kidney transplant--the kidney is not always protected. **AJ. Transpl.** 2009; 9(8): 1957-60.
- Renz j, yersizh D, Farmer J, et al. Changing failed of liver transplantation partial Liver grafts for adults. **J. hepatobiliary surg.** 2003; 10: 31-44.
- Roberto Mazzanti, Laura Gramantier and Luigi Bolondi. Hepatocellular carcinoma: Epidemiology and clinical aspects. **Molecular aspects of med.** 2008; 29(1-2): 130-143.
- Roche B and Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. **J. Viral Hepatol.** 2007; 14: 89–96.
- Roche B and Samuel D. Liver transplantation in viral hepatitis: Prevention of recurrence. **Cli. Gastroentrol.** 2008; 22: 1153-1169.
- Rossi.M, Mennini.G, Lai.Q,et al..Liver transplantation. **J. of Ultrasound** 2007; 10: 28-45.
- Russo M, Firpi R. and Nelson D. et al. Early stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. **Liver Transpl.** 2005; 11: 1235–1241.
- Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for

- right lobe liver transplantation. **Liver Transpl.** 2002; 8: 1114–1122.
- Saab S, Ghobrial RM, Ibrahim AB, et al. positive grafts may be used in orthotopic liver transplantation: a matched analysis. **AJ. Transpl.** 2003; 3: 1167–1172.
 - Said A and Lucey MR. Liver transplantation : an update 2008. **Curr. Opin. Gastroentrol.** 2008; 243: 339-345.
 - Sakashita Hiromi , Hironori Haga, Eishi Ashihara ,et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. **Mod. Pathol.** 2007; 20: 676–684.
 - Sangiovanni A, Fasani P, Ronchi G, et al., The long term course of hepatitis C related cirrhosis. **J. Hepatol.** 2002; 36(1): 177-178.
 - Sawada T, Shimizu A, Kubota K, et al. Lobular damage Caused by cellular humoral immunity in liver allograft Rejection. **Clin. Transpl.** 2005,19:110-114.
 - Schemmer P, Schoonhoven R, Swenberg JA, et al. Gentle organ manipulation during harvest as a key determinant of survival of fatty livers after transplantation in the rat. **Transpl. Int.** 1999; 12: 351–359.
 - Schiano T.D, Gutierrez J.A and Walewski J.A. et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. **Hepatol.** 2005; 42: 1420–1428.

- Schirren CA, Jung MC, Worzfeld T, et al. Hepatitis C virus specific CD4+ T cell response after liver transplantation. **J of infection disease 2001; 183: 1187.**
- Schwartz Myron, Sasan Roayaie and Josep Llovet. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? **.J. of hepatol. 2005; 43(4): 584-589.**
- Sebagh M and Samuel D. Place of the liver biopsy in liver transplantation. **Hepatol. 2004; 41: 897–901.**
- Seki E. and Brenner D.A. The role of NF-kB in hepatocarcinogenesis: promoter or suppressor?. **J. Hepatol . 2007; 47: 307–309.**
- Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. **Semin. Liver Dis. 2001; 21: 105–113.**
- Sheikh Ahmed, Lubna Al-Menawy, Faissal A.M Shaheen, et al. The Diagnosis of Acute Renal Allograft Rejection Using T-lymphocyte Subsets in the Peripheral Blood: A Better Test Now?. **Saudi J of kidney disease and transplantation 2010; 6(1): 15-21.**
- Simeoni J, Fleury S, Dudler J, et al. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. **Eur. J. Cardiothorac. Surg. 2006; 29: 779–783.**
- Sindram D, Porte RJ, Hoffman MR, et al: Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver.**Gstroenterol. 2000; 118: 408-414.**

- Smela M.E, S.S. Currier, E.A. Bailey and J.M. Essigmann. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. **Carcinogenesis** **2001**; **22**: 535–545.
- Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. **Vox. Sang.** **2003**; **84(4)**: 274–86.
- Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. **Hepatol.** **2001**; **34**: 13–18.
- Sterling K. Richard. Gastrointestinal Complications in Liver Transplant Recipients. **Med. Gen. Med.** **2001**; **3(1)**.
- Steven M. Strasberg, Nazia Seizner and Pierre A. Clavien. Principles of Liver Preservation. **Transpl. Liver** **2005**; **38**: 561-573.
- Subramanian S and Ramalingam K .Electron microscopic evidence on the participation Cytotoxic T Lymphocytes and Macrophages in Mtb adjuvant induced connective tissue inflammation and arthritogenesis in Rattus norvegicus. **Asian Journal of Microbiology, Biotechnology and Environmental Sciences** **2005**; **7(2)**: 227-233.
- Sudan.D, A. DeRoover, S. Chinnakotla et al. Radiochemotherapy and transplantation allow long-term survival for non resectable hilar cholangiocarcinoma. **AJ. Transpl.** **2002**; **2**: 774–779.

- Sugawara Y, Makuuchi M and Matsui Y et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. **Transpl. 2004; 78: 1308–1311.**
- Sugawara Y., Makuuchi M., Kaneko J, et al. Living-donor liver transplantation in adults: Tokyo University experience. **J Hepatobiliary Pancreat Surg 2003; 10 (1): 1–4.**
- Surquin M, Le Moine A, Flamand V, et al. IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts. **Transpl. 2005; 80: 1485–1492.**
- Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. **Ann. Surg. 2006; 244: 439–450.**
- Terasaki P.I. Humoral theory of transplant rejection. **AJ transpl. 2003; 3: 665-673.**
- Terrault N, Berenguer M. Treating hepatitis C infection in liver transplant recipients. **Liver Transpl 2006; 12: 1192-1204.**
- Testa G, Malago M, Nadlin S, et al. Right – liver living donor transplantation for decompensate end – stage liver Disease. **liver trasnpl 2003; 8: 340-346.**

- The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. **Hepatol.** 1994; 20:15-20.
- Theodore Sy and Mazen Jamal. Epidemiology of Hepatitis C Virus (HCV) Infection. **Int J Med Sci.** 2006; 3(2): 41–46.
- Touzet S, Kraemer L, Colin C et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Cooperative Research). **Eur. J Gastroenterol. Hepatol.** 2002; 12: 667–678.
- Tran T, Changstri C, Peterson A, et al. living donor liver transplantation: the majority of donors have abnormalities on liver biopsy. **Gastrointrol.** 2003; 348: 818-825.
- Trotter JF. selection of donors and recipients for living donor liver transplantation. **Liver transpl.** 2000; 6: 52-58.
- Unitt Esther, Aileen Marshall, William Gelson, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. **Hepatol.** 2006; 54(3): 246-253.
- Upadhyga GA, Strasberg SM. Platelet adherence to isolated rat hepatic sinusoidal endothelial cells after cold preservation. **Transplantation** 2002; 73: 1764-1770.
- Upadhyga GA, Topp SA, Hotchkiss RS et al: Effect of cold preservation on intracellular calcium concentration and calpain activity in rat sinusoidal endothelial cells. **Hepatol.** 2003; 37: 313-323.

- Urata K, Brault A, Rocheleau B and Huet PM: Role of Kupffer in the survival after rat liver transplantation with long portal vein clamping times. **Transpl. Int.** 2000; 13: 420-427.
- Valujskikh A. The challenge of inhibiting alloreactive T-cell memory. **AJ Transpl.** 2006; 6: 647–651.
- Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. **Liver Transpl.** 2003; 9: 500–505.
- Wakabayashi H, Nishiyama Y, Ushiyama T, Maeba T, Maeta H. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. **J Surg Res** 2002; 106:246–253.
- Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. **Gut** 2002; 51:248–252.
- Weaver C.T, Hatton R.D. Mangan P.R and. Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. **Ann. Rev. Immunol.** 2007; 25: 821–852.
- Werneburg N.W, J.H. Yoon, H. Higuchi and G.J. Gores. Bile acids activate EGF receptor via a TGF- α -dependent mechanism in human cholangiocyte cell lines. **AJ Physiol. Gastrointestinal Liver Physiol.** 2003;285 :31–36.

- Weston J Scott, Rachel L. Leistikow, K. Rajender Reddy, et al. Reconstitution of Hepatitis C Virus–Specific T-Cell–Mediated Immunity After Liver Transplantation. **Hepatol.** 2005; 43: 667.
- Wiesner RH, Menon KV. Late hepatic allograft dysfunction. **Liver Transpl.** 2001; 7: 60–73.
- Williams RS, Alisa AA, Raranu JB, et al. Adult – to –adult living donor liver transplantation. **Eur. J Gastroenterol. Hepatol.** 2003; 15:7-14.
- Winer BJ. Statistical principles in experimental agent. **New York MC Graw Hill** 1992, 28: 6.
- Wulfkuhle J.D, L.A. Liotta and E.F. Petricoin, Proteomic applications for the early detection of cancer. **Nat. Rev. Cancer** 2003; 3: 267–275.
- Wurmbach .E, Y.B. Chen, G. Khitrov, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. **Hepatol.** 2007;45 :938–947
- Yasuhiko Hashikura, Seiji Kawasaki, Shinichi Miyagawa et al. Recent Advance in Living Donor Liver Transplantation. **Liver Transpl.** 2000; 6: 66–72.
- Yilmaz F, Aydin V, Nart D, et al. The incidence and management of acute and chronic rejection after liver transplantation. **Transpl. Proc.** 2006; 38: 1435-1470.

- Young Sun Kim, Hyo K. Lim, Hyunchul Rhim, et al. Recurrence of hepatocellular carcinoma after liver transplantation: pattern and prognostic factors bases on clinical and radiological features. **AJR** 2007; **189**: 352-358.
- Yosry . A, Esmat. G, El-Serafy. M et al. Outcome of Living Donor Liver Transplantation for Egyptian Patients With Hepatitis C (Genotype 4)-Related Cirrhosis. **Transpl. proc.** 2008; **40**(5): 1481-1484.
- Zampieron A, Jayasekera H, Elseviers M, et al. European study on epidemiology and the management of HCV in the haemodialysis population—Part 1:centre policy. **EDTNA ERCA J.** 2004; **30**(2): 84–90.
- Zeeh J, Platt D. The aging liver: structural and functional changes and their consequences for drug treatment in old age. **Gerontology** 2002; **48**: 121–127.
- Zeitlmann, L; Sirim P, Kremmer E, Kolanus W .Cloning of ACP33 as a novel intracellular ligand of CD4. **J. Biol. Chem. (United States)** 2001; **276** (12): 9123–32.
- Zimmerman MA, Trotter JF. Living donor liver transplantation in patient with hepatitis C. **Transpl.** 2003; **9**: 52-57.